Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients

被引:29
|
作者
Lang, H
Schlitt, HJ
Schmidt, H
Flemming, P
Nashan, B
Scheumann, GFW
Oldhafer, KJ
Manns, MP
Raab, R
机构
[1] Univ Essen Gesamthsch Klinikum, Klin & Poliklin Allgemein & Transplantat Chirurg, D-45122 Essen, Germany
[2] Med Hsch Hannover, Abdominal & Transplantat Chirurg Klin, D-30625 Hannover, Germany
[3] Med Hsch Hannover, Gastroenterol & Hepatol Abt, D-30625 Hannover, Germany
[4] Med Hsch Hannover, Abt Pathol, D-30625 Hannover, Germany
关键词
liver transplantation; neuroendocrine pancreatic tumors; hepatic metastases;
D O I
10.1007/s004230050216
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Metastatic neuroendocrine pancreatic tumors have a poor prognosis. We have studied retrospectively the efficacy of liver transplantation as ultimate therapy of otherwise untreatable symptomatic neuroendocrine hepatic metastases originating in the pancreas. Methods: We reviewed our experience of liver transplantation (LTx) for hepatic metastases of neuroendocrine pancreatic tumors in ten patients. The indication for liver grafting was seen in cases of irresectable metastases and when patients were suffering from otherwise untreatable tumor-associated symptoms due to massive hormonal release or large intra-abdominal turner bulk. Results: In four patients, the primary tumors had been removed before LTx, in five patients simultaneously with LTx and in one case 46 months after grafting. There was no operative mortality. After hepatectomy and LTx, all patients had complete relief of symptoms and all preoperatively increased hormonal levels returned to normal. In nine of ten patients, the transplant procedure had the potential for cure, whereas, in one patient, the primary tumor had remained in situ at LTx and was removed 46 months later by an R2-resection. At present, nine patients are alive with a median follow-up of 33 months (range 13.5 months to 117 months). The one patient in whom the primary tumor was removed after transplantation died due to massive intra-abdominal tumor spread 68 months after LTx. Currently, two patients are without evidence of disease, but one of them after re-operation because of lymph-node metastases 8 months after transplantation. The longest disease-free survival is now more than 7 years. In seven of nine patients, tumor recurred between 1.5 months and 48 months after transplantation. Conclusions: Patients with otherwise untreatable symptomatic neuroendocrine hepatic metastases of pancreatic origin may benefit from total hepatectomy and liver transplantation with regard to symptomatic relief and long-term survival, despite frequent recurrence of disease. In some patients, liver transplantation may even offer the chance for cure.
引用
收藏
页码:370 / 377
页数:8
相关论文
共 50 条
  • [1] Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas – a single center experience with ten patients
    H. Lang
    H. J. Schlitt
    H. Schmidt
    P. Flemming
    B. Nashan
    G. F. W. Scheumann
    K. J. Oldhafer
    M. P. Manns
    R. Raab
    Langenbeck's Archives of Surgery, 1999, 384 : 370 - 377
  • [2] Liver Transplantation for Neuroendocrine Tumors: Single Center UCLA Experience
    Soto, Jose
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 84 - 84
  • [3] LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORS: A 15 CASE SINGLE CENTER REPORT
    Moradi, Ali Mohammad
    Mansourian, Mohsenreza
    Rabbani, Amirhassan
    Dahghani, Masoud
    Kazemi, Kourosh
    Shamsaeefar, Alireza
    Ebrahimifam, Somayeh
    Deilami, Hamed Nikoupour
    Eghlimi, Hessam
    Hosseini, Sayed Ali Malek
    Nikeghbalian, Saman
    TRANSPLANT INTERNATIONAL, 2017, 30 : 404 - 404
  • [4] Liver transplantation for patients with metastatic endocrine tumors: Single-center experience with 15 patients
    Frilling, A
    Malago, M
    Weber, F
    Paul, A
    Nadalin, S
    Sotiropoulos, GC
    Cicinnati, V
    Beckebaum, S
    Bockisch, A
    Mueller-Brand, J
    Hofmann, M
    Schmid, KW
    Gerken, G
    Broelsch, CE
    LIVER TRANSPLANTATION, 2006, 12 (07) : 1089 - 1096
  • [5] Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary
    Korda, David
    Doros, Attila
    Piros, Laszlo
    Gerlei, Zsuzsanna
    Haboub-Sandil, Anita
    Mandli, Tamas
    Fazakas, Janos
    Deak, Akos P.
    Mathe, Zoltan
    TRANSPLANTATION PROCEEDINGS, 2019, 51 (04) : 1251 - 1253
  • [6] Liver Transplantation in the Treatment of Neuroendocrine Metastatic Tumors: Our Experience
    Gondolesi, Gabriel
    Pattin, Francisco F.
    Rubio, Santiago S.
    Benitez, Marcela M.
    Cundom, Juan J.
    Barros Schelotto, Pablo P.
    Descalzi, Valeria V.
    TRANSPLANTATION, 2018, 102 : S894 - S894
  • [7] Liver transplantation for metastatic neuroendocrine tumors
    Lang, H
    Oldhafer, KJ
    Weimann, A
    Schlitt, HJ
    Scheumann, GFW
    Flemming, P
    Ringe, B
    Pichlmayr, R
    ANNALS OF SURGERY, 1997, 225 (04) : 347 - 354
  • [8] Liver transplantation for metastatic neuroendocrine tumors
    Barbier, Louise
    Neuzillet, Cindy
    Dokmak, Safi
    Sauvanet, Alain
    Ruszniewski, Philippe
    Belghiti, Jacques
    HEPATIC ONCOLOGY, 2014, 1 (04) : 409 - 420
  • [9] Liver Transplantation for Metastatic Neuroendocrine Tumors
    Florencia Fernandez, Maria
    Barros Schelotto, Pablo
    Mendez, Guillermo
    Descalzi, Valeria
    Gondolesi, Gabriel
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2022, 20 (02) : 228 - 230
  • [10] Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center Experience
    Geramizadeh, Bita
    Kashkooe, Ali
    Malekhosseini, Seyed Ali
    HEPATITIS MONTHLY, 2016, 16 (05)